1.
Lung cancer: current therapies and new targeted treatments
by Hirsch, Fred R, Prof
The Lancet (British edition), 2016, Vol.389 (10066), p.299-311
2.
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label...
by Wu, Yi-Long, Prof
The lancet oncology, 2014, Vol.15 (2), p.213-222
3.
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phas...
by Yang, James Chih-Hsin, Prof
The lancet oncology, 2015, Vol.16 (2), p.141-151
4.
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label,...
by Zhou, Caicun, Prof
The lancet oncology, 2011, Vol.12 (8), p.735-742
5.
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
by Kim, Edward S, MD
The Lancet (British edition), 2008, Vol.372 (9652), p.1809-1818
6.
Sequential chemoradiotherapy followed by sugemalimab for locally advanced NSCLC - Author's reply
by Wu, Yi-Long
The lancet oncology, 2022, Vol.23 (4), p.e159-e159
7.
First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
by Soria, Jean-Charles, Prof
The Lancet (British edition), 2017, Vol.389 (10072), p.917-929
8.
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and L...
by Yang, James C-H, Prof
The lancet oncology, 2015, Vol.16 (7), p.830-838
9.
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
by Ciuleanu, Tudor, MD
The Lancet (British edition), 2009, Vol.374 (9699), p.1432-1440
10.
Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study
by Crinò, Lucio, Prof
The lancet oncology, 2010, Vol.11 (8), p.733-740
11.
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR -mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 ra...
by Soria, Jean-Charles, Prof
The lancet oncology, 2015, Vol.16 (8), p.990-998
12.
Enhancement of Learning and Memory by Elevating Brain Magnesium
by Slutsky, Inna
Neuron (Cambridge, Mass.), 2010, Vol.65 (2), p.165-177
13.
The Effect of Workplace Negative Gossip on Employee Proactive Behavior in China: The Moderating Role of Traditionality
by Wu, Xiangfan
Journal of business ethics, 2018, Vol.148 (4), p.801-815
14.
Dacomitinib in NSCLC: a positive trial with little clinical impact – Authors' reply
by Wu, Yi-Long
The lancet oncology, 2018, Vol.19 (1), p.e5-e5
15.
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
by Shi, Yuankai, MD
The lancet oncology, 2013, Vol.14 (10), p.953-961
16.
Prospective radiotherapy for patients with oropharyngeal carcinoma
by Wang, Yue
The lancet oncology, 2017, Vol.18 (8), p.e425-e425
17.
Comprehensive identification of peptides in tandem mass spectra using an efficient open search engine
by Chi, Hao
Nature biotechnology, 2018, Vol.36 (11), p.1059-1061
18.
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
by Zhong, Wen-Zhao
The lancet oncology, 2018, Vol.19 (1), p.139-148
19.
The second wave of checkpoint inhibitors with chemotherapy for advanced non-small-cell lung cancer
by Li, Yangqiu
The lancet oncology, 2019, Vol.20 (7), p.889-891
20.
Roles of NMDA NR2B Subtype Receptor in Prefrontal Long-Term Potentiation and Contextual Fear Memory
by Zhao, Ming-Gao
Neuron (Cambridge, Mass.), 2005, Vol.47 (6), p.859-872
